Keywords: Merck & Co, AiCuris, HCMV, Cytomegaloviris, Letermovir

Merck & Co in-licenses portfolio targeting HCMV from AiCuris for up to $570 million

Article | 16 October 2012

Print This

US pharma giant Merck & Co (NYSE: MRK) has entered into an exclusive worldwide licensing agreement with Germany’s ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in